Sec. 32-39p. Connecticut 500 Project. Goals. Solicitation of bids.
Sec. 32-39p. Connecticut 500 Project. Goals. Solicitation of bids. Section 32-39p is repealed, effective July 1, 2023.
(May Sp. Sess. P.A. 16-3, S. 20; P.A. 23-204, S. 444.)
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |
Sec. 32-41kk. (Formerly Sec. 19a-32e). Regenerative Medicine Research Fund. Application for financial assistance. Available funding. (a) There is established the “Regenerative Medicine Research Fund”, which shall be a separate, nonlapsing account within the General Fund. The fund may contain any moneys required or permitted by law to be deposited in the fund and any funds received from any public or private contributions, gifts, grants, donations, bequests or devises to the fund. The chief executive officer of Connecticut Innovations, Incorporated, (1) shall award financial assistance from the fund in accordance with the provisions of subsection (b) of this section, and (2) may enter into agreements with other entities, including, but not limited to, the government of any state or foreign country for the purpose of advancing research collaboration opportunities for recipients of financial assistance under this section.
(b) The chief executive officer of Connecticut Innovations, Incorporated, shall develop an application for financial assistance under this section for the purpose of conducting regenerative medicine research and may receive applications from eligible institutions for such financial assistance. The chief executive officer of Connecticut Innovations, Incorporated, shall require any applicant for financial assistance under this section to conduct regenerative medicine research to submit (1) a complete description of the applicant's organization, (2) the applicant's plans for regenerative medicine research and proposed funding for such research from sources other than the state, (3) proposed arrangements concerning financial benefits to the state as a result of any patent, royalty payment or similar rights developing from any proposed research made possible by the awarding of such financial assistance, and (4) a form attesting to compliance with subsections (c) and (d) of section 32-41jj if the regenerative medicine research involves the use of embryonic stem cells.
(c) Commencing with the fiscal year ending June 30, 2006, and for each of the thirteen consecutive fiscal years thereafter, until the fiscal year ending June 30, 2019, funds shall be available from the Regenerative Medicine Research Fund for financial assistance to eligible institutions for the purpose of conducting regenerative medicine research. Any funds not used for such financial assistance during a fiscal year shall be carried forward for the fiscal year next succeeding for such financial assistance.
(P.A. 05-149, S. 2; P.A. 14-98, S. 33; P.A. 15-222, S. 2; 15-242, S. 5; June Sp. Sess. P.A. 17-2, S. 452; P.A. 23-204, S. 241.)
History: P.A. 05-149 effective June 15, 2005; P.A. 14-98 amended Subsec. (a) by replacing “Stem Cell Research Fund” with “Regenerative Medicine Research Fund”, changing administration of fund from Commissioner of Public Health to chief executive officer of Connecticut Innovations, Incorporated, designating existing provision re grants-in-aid as Subdiv. (1) and adding Subdiv. (2) re agreements with other entities, amended Subsec. (b) by replacing “Stem Cell Research Advisory Committee” with “Regenerative Medicine Research Advisory Committee”, amended Subsec. (c) by extending sunset date for grants-in-aid from June 30, 2015, to June 30, 2019, and made technical and conforming changes; Sec. 19a-32e transferred to Sec. 32-41kk in 2015; P.A. 15-222 replaced references to grants-in-aid with references to financial assistance and amended Subsec. (b) by replacing reference to Regenerative Medicine Research Peer Review Committee with reference to peer reviewers pursuant to Sec. 32-41mm, effective July 1, 2015; P.A. 15-242 amended Subsec. (b) by adding Subdiv. (4) re compliance form; June Sp. Sess. P.A. 17-2 amended Subsec. (c) by replacing “not less than ten million dollars” with “funds” and “balance of such amount” with “funds”, effective October 31, 2017; P.A. 23-204 amended Subsec. (b) by replacing references to Regenerative Medicine Research Advisory Committee with chief executive officer of Connecticut Innovations, Incorporated and deleting provision re advisory committee directing the chief executive officer re financial assistance awards, effective July 1, 2023.
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |
Sec. 32-41ll. (Formerly Sec. 19a-32f). Development of donated funds program to encourage regenerative medicine research. Administration of Regenerative Medicine Research Fund. (a) The chief executive officer of Connecticut Innovations, Incorporated, shall (1) develop a donated funds program to encourage the development of funds other than state appropriations for regenerative medicine research in the state, (2) examine and identify specific ways to improve and promote for-profit and not-for-profit regenerative medicine research and research in related areas in the state, including, but not limited to, identifying both public and private funding sources for such research, maintaining existing regenerative medicine-related businesses, recruiting new regenerative medicine-related businesses to the state and recruiting scientists and researchers in such field to the state, (3) administer a regenerative medicine research assistance program that shall provide financial assistance to eligible institutions for the advancement of regenerative medicine research in the state pursuant to section 32-41kk, (4) monitor the regenerative medicine research conducted by eligible institutions that receive such financial assistance, and (5) prepare a comprehensive strategic plan for the Regenerative Medicine Research Fund, established pursuant to section 32-41kk, and financial assistance awarded from said fund that shall include, but need not be limited to, identification of specific methods or strategies to (A) achieve the scientific and economic development objective of said fund, (B) build innovation capacity, and (C) sustain investments of moneys received by said fund.
(b) Connecticut Innovations, Incorporated, shall serve as administrator of the Regenerative Medicine Research Fund and shall: (1) Develop the application for the financial assistance authorized under subsection (b) of section 32-41kk; (2) review such applications; (3) review recommendations of peer reviewers pursuant to section 32-41mm; (4) prepare and execute any assistance agreements or other agreements in connection with the awarding of such financial assistance; (5) develop performance metrics and systems to collect data from recipients of such financial assistance; and (6) collect information from such recipients concerning each recipient's employment statistics, business accomplishments and performance outcomes, peer review articles and papers published, partnerships and collaborations with other entities, licenses, patents and invention disclosures, scientific progress as it relates to the commercialization of intellectual property funded by such financial assistance, efforts to commercialize such intellectual property, and other funds received for research.
(P.A. 05-149, S. 3; P.A. 06-33, S. 1; P.A. 10-117, S. 43; P.A. 11-242, S. 39; P.A. 14-98, S. 34; P.A. 15-55, S. 1; 15-222, S. 3; P.A. 23-204, S. 240.)
History: P.A. 05-149 effective June 15, 2005; P.A. 06-33 amended Subsec. (a) by designating existing provisions as Subdiv. (1) and adding Subdiv. (2) requiring the appointment of eight additional members by July 1, 2006, and amended Subsec. (d) by describing what shall not constitute a conflict of interest and authorizing members to participate in the review or consideration of grant-in-aid applications, effective April 24, 2006; P.A. 10-117 deleted former Subsec. (g) re annual reports from committee to Governor and General Assembly; P.A. 11-242 amended Subsec. (a)(1) by permitting commissioner's designee to be a member of committee and amended Subsec. (b) by permitting commissioner's designee to serve as committee chairperson; P.A. 14-98 amended Subsec. (a) by replacing “Stem Cell Research Advisory Committee” with “Regenerative Medicine Research Advisory Committee”, adding chief executive officer of Connecticut Innovations, Incorporated, as member, adjusting qualifications for members appointed by Governor and minority leader of the House of Representatives, and removing restriction on members' concurrent service on peer review committee in Subdiv. (1), and adjusting qualifications for members appointed by Governor, president pro tempore of the Senate, speaker of the House of Representatives and minority leader of the House of Representatives, and removing restriction on members' concurrent service on peer review committee in Subdiv. (2), deleted former Subsec. (b) re Commissioner of Public Health as chairperson, added new Subsec. (b) re chief executive officer of Connecticut Innovations, Incorporated, as chairperson, amended Subsec. (e) by adding Subdiv. (5) re strategic plan, amended Subsec. (f) by replacing former provisions with provisions re duties of Connecticut Innovations, Incorporated, and replaced references to embryonic and human adult stem cell with references to regenerative medicine and made technical and conforming changes throughout; Sec. 19a-32f transferred to Sec. 32-41ll in 2015; P.A. 15-55 amended Subsec. (f)(2) by replacing “Regenerative Medicine Research Advisory Committee” with “Regenerative Medicine Peer Review Committee”, effective June 19, 2015; P.A. 15-222 replaced references to grants-in-aid with references to financial assistance and made conforming changes in Subsecs. (d) to (f), and amended Subsec. (f)(3) by replacing reference to Regenerative Medicine Research Advisory Committee with reference to peer reviewers, effective July 1, 2015; P.A. 23-204 deleted former Subsecs. (a) to (d) re establishment and membership of Regenerative Medicine Research Advisory Committee, redesignated existing Subsec. (e) as Subsec. (a) and amended same to replace reference to advisory committee with chief executive officer of Connecticut Innovations, Incorporated and made a conforming change and redesignated existing Subsec. (f) as Subsec. (b) and amended same to delete reference to advisory committee and delete former Subdiv. (7) re administrative duties, effective July 1, 2023.
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |
Sec. 32-41mm. (Formerly Sec. 19a-32g). Peer review of applications for financial assistance. Qualifications and duties of peer reviewers. Rating and scoring guidelines. (a) Prior to the awarding of any financial assistance in response to an application submitted pursuant to section 32-41kk, the chief executive officer of Connecticut Innovations, Incorporated, shall contract with a third party for the selection of peer reviewers to review such application and make recommendations to said officer with respect to the ethical and scientific merit of such application.
(b) Such peer reviewers shall: (1) Have a demonstrated knowledge and understanding of the ethical and medical implications of regenerative medicine research or related research fields, including, but not limited to, embryology, genetics or cellular biology; (2) have practical research experience in regenerative medicine research or related research fields, including, but not limited to, embryology, genetics or cellular biology; (3) work to advance regenerative medicine research; and (4) become and remain fully cognizant of the National Academies' Guidelines for Human Embryonic Stem Cell Research, as amended from time to time, and shall utilize said guidelines to evaluate any application pursuant to subsection (a) of this section.
(c) No peer reviewer shall review any application filed by such peer reviewer or by any eligible institution in which such peer reviewer has a financial interest, or with which such peer reviewer engages in any business, employment, transaction or professional activity.
(d) Such peer reviewers may receive compensation from Connecticut Innovations, Incorporated, for reviewing applications submitted pursuant to section 32-41kk. The rate of compensation shall be established by the board of directors of Connecticut Innovations, Incorporated.
(e) The chief executive officer of Connecticut Innovations, Incorporated, shall establish guidelines for the rating and scoring of such applications. In establishing such guidelines, said officer may consult with a third party contracted for the selection of peer reviewers pursuant to subsection (a) of this section.
(P.A. 05-149, S. 4; P.A. 06-196, S. 209; P.A. 07-252, S. 40; P.A. 08-80, S. 2; P.A. 11-242, S. 19; P.A. 14-98, S. 35; P.A. 15-222, S. 4; P.A. 23-204, S. 242.)
History: P.A. 05-149 effective June 15, 2005; P.A. 06-196, made technical changes in Subsec. (b), effective June 7, 2006; P.A. 07-252 amended Subsec. (a) by designating existing provisions as Subdiv. (1), redesignating existing Subdivs. (1), (2) and (3) as Subparas. (A), (B) and (C), respectively, and adding new Subdiv. (2) authorizing Commissioner of Public Health to appoint additional members to Stem Cell Research Peer Review Committee, provided total membership does not exceed 15, effective July 1, 2007; P.A. 08-80 amended Subsec. (e) to require that Academies' Guidelines for Human Embryonic Stem Cell Research be utilized to evaluate each grant-in-aid application and to make technical changes; P.A. 11-242 amended Subsec. (a)(2) by making a technical change, added new Subsec. (d) re compensation to peer review committee members and redesignated existing Subsecs. (d) and (e) as Subsecs. (e) and (f); P.A. 14-98 amended Subsec. (a) by replacing “Stem Cell Research Peer Review Committee” with “Regenerative Medicine Research Peer Review Committee”, deleting former Subdiv. (2) re appointment of additional members, redesignating existing provisions re member qualifications as new Subdiv. (2), and adding Subdiv. (3) re membership transition from those appointed by Commissioner of Public Health to those appointed by chief executive officer of Connecticut Innovations, Incorporated, amended Subsec. (d) by changing compensation for members from Stem Cell Research Fund to Connecticut Innovations, Incorporated, amended Subsec. (f) by deleting provision re guideline recommendations, and replaced references to embryonic or human adult stem cell with references to regenerative medicine and made technical and conforming changes throughout; Sec. 19a-32g transferred to Sec. 32-41mm in 2015; P.A. 15-222 replaced former Subsecs. (a) to (c) re Regenerative Medicine Research Peer Review Committee with new Subsecs. (a) to (c) re peer review of applications for financial assistance, amended Subsec. (d) by replacing reference to committee with reference to peer reviewers and replacing “grant-in-aid applications submitted by eligible institutions” with “applications submitted pursuant to section 32-41kk”, amended Subsec. (e) by replacing “Regenerative Medicine Research Peer Review Committee” with “Regenerative Medicine Research Advisory Committee” and adding provisions re establishment of guidelines for rating and consultation with a third party, and deleted former Subsec. (f) re guidelines, effective July 1, 2015; P.A. 23-204 amended Subsecs. (a) and (e) by replacing references to Regenerative Medicine Research Advisory Committee with chief executive officer of Connecticut Innovations, Incorporated, effective July 1, 2023.
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |